Why Nib shares are on the move after its latest update

Nib shares lift after announcing an approved 2026 health premium change.

Shares in Nib Holdings Ltd (ASX: NHF) are higher in early morning trade after the health insurance provider released an update following market close yesterday.

At the time of writing, the Nib share price is up 3.45% to $6.60.

Here is what investors need to know.

Stethoscope with a piggy bank in the middle.

Image source: Getty Images

Premium increases confirmed for 2026

In an ASX announcement, Nib confirmed that its private health insurance premiums will rise by an average of 5.47%.

The increase follows approval from the Federal Minister for Health and Aged Care.

Management said the changes reflect ongoing cost pressures across the healthcare system. These include higher hospital and medical costs, increased use of services, and broader inflationary impacts.

The company noted that more than half of its policyholders will see increases of $3.80 per week or less.

Chief Executive Officer Ed Close said Nib remains focused on affordability and value, while continuing to manage rising claims costs.

During FY25, the group paid $2.3 billion in claims, an increase of almost 9% on the prior year. The company also recorded more than 400,000 hospital admissions and 4.3 million visits to medical providers.

Momentum and key price levels

Looking at the chart, Nib shares have trended lower since late 2025 after peaking above $8 during the year.

The stock closed at $6.38 on Tuesday and is hovering around $6.60 in early trade. Over the past 12 months, it has traded between $5.82 and $8.26.

On the daily chart, Nib is trading near the lower end of that range. The price is closer to the lower Bollinger Band, suggesting softer short-term momentum.

The relative strength index (RSI) is around 40, placing the stock near oversold territory but not at extreme levels. This suggests selling pressure may be easing, though momentum remains weak.

The $5.80 to $6 zone has acted as support over the past year. On the upside, resistance appears near $7, with further resistance around $7.50 based on prior trading activity.

With the shares closer to support than their 12-month high, the next move may hinge on whether support holds.

What investors will be watching next

Premium adjustments are a normal part of the private health insurance cycle and are closely linked to claims trends and healthcare cost inflation.

While higher premiums can support revenue growth, investors will also be monitoring policyholder retention and membership growth in the months ahead.

Nib is scheduled to release its half-year results on Monday, 23 February. The update will provide further detail on margins, claims trends, and management's outlook for the remainder of the year.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Would I buy ResMed shares after today's results?

The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Why are Mesoblast shares racing 15% higher today?

Find out what caught investor interest.

Read more »